遺伝子サイレンシング市場- 世界の産業規模、シェア、動向、機会、予測、製品・サービス別、用途別、地域別、競争別セグメント、2020-2030F

遺伝子サイレンシングの世界市場規模は2024年に28億6,000万米ドルで、2030年には43億6,000万米ドルに達すると予測され、予測期間中にCAGR7.48％で拡大すると予測されます。

この市場は、分子生物学の急速な進歩、精密医療の重視の高まり、遺伝的疾患を標的とした効果的な治療法のニーズの高まりに後押しされ、力強い成長を遂げています。遺伝子サイレンシング-特定の遺伝子の発現を抑制または阻害するために使用される技術-は、がん、ウイルス感染症、神経疾患など幅広い疾患の治療開発において重要なツールとなっています。

遺伝子機能に対する科学的理解が深まり、研究活動が世界的に拡大する中、遺伝子サイレンシングは将来のヘルスケアと創薬において変革的な役割を果たすことが期待されています。

市場促進要因

ヘルスケア産業の拡大と精密医療への需要

主な市場課題

送達メカニズムの限界

主要市場動向

RNAベースの治療薬への関心の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の遺伝子サイレンシング市場に与える影響

第5章 世界の遺伝子サイレンシング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品・サービス別（RNAi、CRISPR-Cas9、アンチセンスオリゴヌクレオチド、その他）
  • 用途別（神経学、腫瘍学、感染症、代謝性疾患、治療薬製造、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の遺伝子サイレンシング市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の遺伝子サイレンシング市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の遺伝子サイレンシング市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の遺伝子サイレンシング市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの遺伝子サイレンシング市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 世界の遺伝子サイレンシング市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Revvity, Inc.
• Danaher Corporation
• Agilent Technologies, Inc.
• GenScript Biotech Corporation
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• New England Biolabs, Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Gene Silencing Market was valued at USD 2.86 billion in 2024 and is projected to reach USD 4.36 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.48% during the forecast period.

This market is witnessing strong growth, fueled by rapid advancements in molecular biology, increasing emphasis on precision medicine, and the growing need for effective therapies targeting genetic conditions. Gene silencing-a technique used to suppress or inhibit the expression of specific genes-has become a critical tool in therapeutic development for a broad spectrum of diseases, including cancer, viral infections, and neurological disorders.

As scientific understanding of gene function continues to deepen and research activities expand globally, gene silencing is poised to play a transformative role in the future of healthcare and drug discovery.

Key Market Drivers

Expanding Healthcare Industry and Demand for Precision Medicine

The healthcare sector's transition toward personalized and targeted treatments is a major catalyst for the adoption of gene silencing technologies such as RNA interference (RNAi) and antisense oligonucleotides (ASOs). RNAi, in particular, offers a rapid and effective mechanism for silencing gene expression across various organisms. It operates by breaking down double-stranded RNA into smaller fragments, which then activate enzymes to selectively degrade corresponding messenger RNA (mRNA), ultimately preventing the production of disease-associated proteins.

These technologies enable a high degree of specificity, allowing for the selective suppression of disease-causing genes while sparing healthy tissues-an approach that is especially valuable in areas like oncology, where conventional treatments may be less effective and can cause harmful side effects.

The increasing prevalence of genetic and rare diseases further underscores the need for gene silencing therapies. Disorders such as thalassemia, sickle cell anemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency-which are often caused by single-gene mutations-represent ideal candidates for gene-targeted approaches. These conditions exhibit substantial molecular and clinical diversity both across and within populations, highlighting the necessity for tailored therapeutic strategies.

Key Market Challenges

Limitations in Delivery Mechanisms

Despite promising developments, the effective delivery of gene silencing agents remains a significant challenge. These molecules must successfully navigate complex biological barriers to reach their intended targets while avoiding degradation by enzymes or clearance by the immune system. Natural defenses-such as nucleases that break down RNA-can compromise the stability and efficacy of these agents before they reach their target cells.

In addition, target-specific delivery remains a critical hurdle. For gene silencing therapies to achieve therapeutic benefit, they must selectively silence disease-related genes without impacting healthy gene expression. However, existing delivery systems often lack the required precision, raising concerns about off-target effects and unintended gene suppression, which can lead to adverse outcomes. This limitation in delivery efficiency and specificity continues to restrict the widespread clinical translation of gene silencing technologies.

Key Market Trends

Rising Interest in RNA-Based Therapeutics

The momentum behind RNA-based therapies-including RNAi and ASOs-continues to grow rapidly. Currently, there are 18 clinically approved RNA-based drugs, including two mRNA vaccines that became globally recognized during the COVID-19 pandemic. These developments have brought RNA-based science into the mainstream, extending its applications from global health emergencies to rare, individualized conditions.

RNAi therapeutics work by degrading specific mRNA molecules, thereby halting the production of disease-causing proteins. ASOs, meanwhile, bind to mRNA sequences to inhibit translation or trigger degradation. These targeted approaches offer precise regulation of gene expression, making them ideal for addressing diseases at the genetic level.

The customizability of RNA-based therapies allows for the treatment of rare and previously untreatable genetic disorders, positioning gene silencing as a cutting-edge solution in modern medicine. Notable approvals such as Patisiran (for hereditary transthyretin-mediated amyloidosis) and Nusinersen (for spinal muscular atrophy) underscore the clinical viability and therapeutic promise of these approaches.

Key Market Players

• Revvity, Inc.
• Danaher Corporation
• Agilent Technologies, Inc.
• GenScript Biotech Corporation
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• New England Biolabs, Inc.

Report Scope

In this report, the Global Gene Silencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Silencing Market, By Product & Service:

• RNAi
• CRISPR-Cas9
• Antisense Oligonucleotides
• Others

Gene Silencing Market, By Application:

• Neurology
• Oncology
• Infectious Diseases
• Metabolic Diseases
• Therapeutics Manufacturing
• Others

Gene Silencing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Silencing Market.

Available Customizations:

Global Gene Silencing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Gene Silencing Market

5. Global Gene Silencing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (RNAi, CRISPR-Cas9, Antisense Oligonucleotides, Others)
  • 5.2.2. By Application (Neurology, Oncology, Infectious Diseases, Metabolic Diseases, Therapeutics Manufacturing, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Gene Silencing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gene Silencing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Application
  • 6.3.2. Mexico Gene Silencing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Application
  • 6.3.3. Canada Gene Silencing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Application

7. Europe Gene Silencing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Gene Silencing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Gene Silencing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Gene Silencing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Gene Silencing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Gene Silencing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Application

8. Asia Pacific Gene Silencing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gene Silencing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Application
  • 8.3.2. India Gene Silencing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Application
  • 8.3.3. South Korea Gene Silencing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Application
  • 8.3.4. Japan Gene Silencing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Gene Silencing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Application

9. South America Gene Silencing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Gene Silencing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Gene Silencing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Gene Silencing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Application

10. Middle East and Africa Gene Silencing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Gene Silencing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Gene Silencing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Gene Silencing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gene Silencing Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Revvity, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Danaher Corporation
• 15.3. Agilent Technologies, Inc.
• 15.4. GenScript Biotech Corporation
• 15.5. Merck KGaA
• 15.6. Thermo Fisher Scientific, Inc.
• 15.7. Illumina, Inc.
• 15.8. Bio-Rad Laboratories, Inc.
• 15.9. Bio-Techne Corporation
• 15.10. New England Biolabs, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer